Original reporting and analysis on the stories shaping biotech.
Enveda Biosciences just dropped Phase 1 data on a pill that mimics what your body produces after a hard workout. It's not trying to replace Ozempic; it's trying to solve the massive problem of what happens when you stop taking it.
AstraZeneca's Tagrisso just got a powerful sidekick. The Phase III SAFFRON trial showed that adding Hutchmed's Orpathys extended survival in lung cancer patients whose tumors outsmarted first-line treatment, and the implications stretch far beyond one clinical readout.
David Baker's GenBio AI just unveiled a virtual cell that claims to simulate human biology from DNA to whole-cell behavior in one AI system. It's the boldest bet yet in computational biology, and the early results are turning heads.
CSL posted a $2.6 billion net loss and its stock soared 18%, the best single-day move in 25 years. Behind the apparent contradiction lies a "reset year" ending, a massive buyback, and a plasma market where demand keeps outrunning supply.
Argenx is paying $2.2 billion in cash for Forte Biosciences, a clinical-stage company most investors have barely heard of. The deal reveals how the VYVGART maker plans to break free from its one-mechanism identity and compete in immunology's escalating M&A arms race.
Eli Lilly is paying up to $2.4 billion for Orna Therapeutics and its circular RNA platform, betting it can reprogram immune cells inside the body. It's the pharma giant's boldest bet yet on a technology that hasn't been proven in humans.
Moderna and Merck just reported the first-ever positive Phase 3 results for a personalized cancer vaccine, one that's built from scratch using each patient's own tumor DNA. It could reshape how we treat cancer after surgery, and Wall Street is calling it a make-or-break moment.
The FDA just approved an engineered herpes virus to treat melanoma that resists standard immunotherapy. It's a milestone for oncolytic virus therapy and a lifeline for patients running out of options.
A three-year-old AI startup from Chicago just licensed a Chinese cancer drug in a deal worth over $2 billion. The bet: a first-in-class bispecific ADC that attacks tumors through two targets at once, aimed at one of oncology's most stubborn cancers.
Regeneron pulled the plug on its TITAN trial after a mysterious safety event forced an unfavorable risk-benefit call on its uveitis drug REGN7041. It's the company's second pipeline stumble of 2026, and it raises the stakes for a critical geographic atrophy readout later this year.
LEO Pharma is spending up to $435 million on a drug that isn't even approved yet. But dersimelagon could be the first real treatment for a brutal sun allergy, and LEO's rare-dermatology shopping spree is starting to look like a masterplan.
Amylyx was left for dead after its ALS drug imploded. Two years later, a $35 million acquisition just delivered Phase 3 data so strong it could create the first approved treatment for a post-surgical complication nobody's been able to fix.
Argenx's Vyvgart Hytrulo aced its Phase 3 trial in autoimmune myositis, but one subtype missed the statistical mark. Wall Street didn't seem to mind, sending shares up over 13%, and the real story is what this means for a rare disease with zero approved therapies.
Fulcrum Therapeutics gutted its pipeline and laid off 85% of its staff. Now a migraine startup is using it as a shortcut to Nasdaq, and eight heavyweight investors just piled $245 million into the deal.
Evaxion just killed its tumor vaccine program and went all-in on an AI-designed brain cancer candidate with zero clinical data. With $18 million in cash and a ticking clock, this is either a brilliant survival move or a very expensive Hail Mary.
Sanofi just cut 229 Blueprint Medicines employees, roughly a third of the company's pre-acquisition workforce, barely a year after closing its $9.5 billion deal. The layoffs fit a growing pattern of faster, more aggressive post-deal integration across pharma, and they raise a pointed question: can big pharma absorb precision medicine companies without gutting what made them valuable?
MoonLake's sonelokimab nailed every endpoint in a pivotal psoriatic arthritis trial. The stock dropped anyway. A look at the results, the trust deficit, and why Wall Street isn't buying what MoonLake is selling.
The FDA just approved a microscopic radioactive implant for bile duct cancer, one of oncology's most neglected diseases. OncoSil's approval marks the first Class III device cleared for this indication, and it signals a growing trend of device-oncology hybrids tackling cancers that pharma left behind.
EyePoint's DURAVYU promised to cut eye injections from monthly to twice a year. Its first pivotal trial delivered stunning durability data but missed the primary endpoint, leaving investors with a Rorschach test instead of a clear answer.
Biotech startups raised over $9.1 billion in H1 2026, the best first half in four years. But cancer and autoimmune companies hoarded more than 40% of the money, and early-stage startups are getting squeezed like never before. The rebound is real; so is the growing divide.
Sandoz just committed up to $322 million to license biosimilars from a Chinese company most people have never heard of. The deal with Shanghai Henlius signals something bigger: China's biologics ecosystem has gone from follower to supplier for the world's largest biosimilar company.
While the rest of pharma fights over GLP-1s and oncology biologics, Eli Lilly just dropped $370 million on one of the most notoriously difficult drug target classes in biology. The OmniAb collaboration is either a visionary contrarian bet or an expensive science experiment.
Join thousands of biotech professionals who start their day with our free, daily briefing.